These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26668309)

  • 1. A Novel Naphthalimide Compound Restores p53 Function in Non-small Cell Lung Cancer by Reorganizing the Bak·Bcl-xl Complex and Triggering Transcriptional Regulation.
    Zhang G; An Y; Lu X; Zhong H; Zhu Y; Wu Y; Ma F; Yang J; Liu Y; Zhou Z; Peng Y; Chen Z
    J Biol Chem; 2016 Feb; 291(8):4211-25. PubMed ID: 26668309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells.
    Zhang GH; Yuan JM; Qian G; Gu CX; Wei K; Mo DL; Qin JK; Peng Y; Zhou ZP; Pan CX; Su GF
    J Med Chem; 2017 Aug; 60(16):6853-6866. PubMed ID: 28745887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting serine 392 phosphorylation.
    Li L; Li P; Ma X; Zeng S; Peng Y; Zhang G
    Biochem Pharmacol; 2022 Sep; 203():115188. PubMed ID: 35902040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-X(L)/p53-mediated amplification mechanisms.
    Shi YL; Feng S; Chen W; Hua ZC; Bian JJ; Yin W
    Cell Death Dis; 2014 Dec; 5(12):e1579. PubMed ID: 25522273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor suppressor protein p53 promotes 2-methoxyestradiol-induced activation of Bak and Bax, leading to mitochondria-dependent apoptosis in human colon cancer HCT116 cells.
    Lee JY; Jee SB; Park WY; Choi YJ; Kim B; Kim YH; Jun do Y; Kim YH
    J Microbiol Biotechnol; 2014 Dec; 24(12):1654-63. PubMed ID: 25179905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.
    Nieminen AI; Eskelinen VM; Haikala HM; Tervonen TA; Yan Y; Partanen JI; Klefström J
    Proc Natl Acad Sci U S A; 2013 May; 110(20):E1839-48. PubMed ID: 23589839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G1 phase cell cycle arrest in NSCLC in response to LZ-106, an analog of enoxacin, is orchestrated through ROS overproduction in a P53-dependent manner.
    Yang L; Zhou J; Meng F; Fu C; Zou X; Liu J; Zhang C; Tan R; Li Z; Guo Q; Wei L
    Carcinogenesis; 2019 Mar; 40(1):131-144. PubMed ID: 30239617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J; Huang K; O'Neill KL; Pang X; Luo X
    Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule MX-C2/3 suppresses non-small cell lung cancer progression via p53 activation.
    Li L; Du W; Wang H; Zhao Y; Huang Z; Peng Y; Zeng S; Zhang G
    Chem Biol Interact; 2022 Oct; 366():110142. PubMed ID: 36058261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
    Meiler J; Guyot M; Hoffarth S; Wesarg E; Höhn Y; Breitenbuecher F; Schuler M
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1385-94. PubMed ID: 22488173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways.
    Pirouzpanah MB; Sabzichi M; Pirouzpanah S; Chavoshi H; Samadi N
    Asian Pac J Cancer Prev; 2015; 16(5):2087-92. PubMed ID: 25773855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
    Chen Y; Li H; Zhang W; Qi W; Lu C; Huang H; Yang Z; Liu B; Zhang L
    Toxicol Appl Pharmacol; 2020 Jan; 387():114848. PubMed ID: 31809756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhizoma Paridis Saponins Induces Cell Cycle Arrest and Apoptosis in Non-Small Cell Lung Carcinoma A549 Cells.
    Zhang J; Yang Y; Lei L; Tian M
    Med Sci Monit; 2015 Aug; 21():2535-41. PubMed ID: 26311066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical assessment of apoptosis-associated proteins: p53, Bcl-xL, Bax and Bak in gastric cancer cells in correlation with clinical and pathomorphological factors.
    Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kamocki Z; Zaręba K; Kemona A; Kędra B
    Adv Med Sci; 2012 Jun; 57(1):77-83. PubMed ID: 22440942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
    Kriegs M; Gurtner K; Can Y; Brammer I; Rieckmann T; Oertel R; Wysocki M; Dorniok F; Gal A; Grob TJ; Laban S; Kasten-Pisula U; Petersen C; Baumann M; Krause M; Dikomey E
    Radiother Oncol; 2015 Apr; 115(1):120-7. PubMed ID: 25796091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
    Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
    Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel compound PS-101 exhibits selective inhibition in non-small-cell lung cancer cell by blocking the EGFR-driven antiapoptotic pathway.
    Zhang GH; Cai LJ; Wang YF; Zhou YH; An YF; Liu YC; Peng Y; Chen ZF; Liang H
    Biochem Pharmacol; 2013 Dec; 86(12):1721-30. PubMed ID: 24161785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.